[PAGE-B with Moderate HBV DNA Levels Predicts Risk of Hepatocellular Carcinoma among Patients at Phase Change from Immuno-tolerant Phase to Immune-active Phase in HBeAg-Positive Chronic Hepatitis B]

[在HBeAg阳性慢性乙型肝炎患者中,处于免疫耐受期向免疫活跃期转变阶段的患者,PAGE-B 检测结果中等HBV DNA水平可预测肝细胞癌风险]

阅读:2

Abstract

BACKGROUND: The sialic‐acid binding immunoglobulin‐like lectin 3 receptor (Siglec‐3 / CD33) is one of the highly associated AD risk genes. Previous studies revealed that the non‐coding AD‐risk alleles (rs3865444 and rs12459419) are associated with increased total levels of CD33 expression and a higher relative expression of the long CD33(M) splice form. However, the molecular basis of the immuno‐inhibitory function of CD33 remains unclear. METHOD: To confirm the presence of CD33 dimers, we conducted multiple experiments. Blue Native Gel electrophoresis and co‐immunoprecipitation assays were used to detect CD33 bands corresponding to the expected molecular weights. Flow cytometry with specific antibodies was performed to quantify cell‐surface CD33. Additionally, single‐molecule fluorescence resonance energy transfer (smFRET) combined with TIRF imaging was employed to visualize CD33 dimers on the cell surface. Furthermore, Western Blotting of phosphorylation of CD33 and its downstream molecule were performed to verify if the dimers were functional. RESULT: Biochemical analyses demonstrated that CD33(M) and CD33(m) can form homodimers or heterodimers. Flow cytometry confirmed that CD33(M) isoforms are selectively trafficked to the cell surface, while smFRET imaging verified the presence of dimers on the cell surface. The elevation of the CD33 pathway following stimulation with CD33‐specific ligands provided evidence that CD33(M) homodimers are functional. CONCLUSION: This study reveals the critical role of CD33(M) in AD pathology by elucidating its molecular mechanisms. We provide direct evidence that CD33(M) and CD33(m) isoforms can form both homodimers and heterodimers. However, only CD33(M) isoforms are preferentially trafficked to the cell surface and form functional dimers. These findings advance our understanding of the molecular basis of CD33's immuno‐inhibitory function and offer new insights into its involvement in AD risk, potentially paving the way for the development of targeted therapeutic strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。